特發性肺纖維化市場規模、佔有率、成長分析，按藥物類型、作用機制、最終用戶和地區分類 - 產業預測，2024-2031

2022年全球特發性肺纖維化市場規模預估為35億美元，預測期間（2024-2031年）複合年成長率為6.98%，從2023年的40.2億美元增加至2031年的10.8億美元。

全球特發性肺纖維化（IPF）市場正在經歷顯著成長，這種嚴重肺部疾病的盛行率不斷上升，其特徵是進行進行性肺組織疤痕形成和功能障礙。這個市場的擴張主要歸功於診斷技術的進步，這些技術增強了早期檢測並實現了更好的疾病管理，以及醫療保健專業人員和患者對及時干預的必要性的認知不斷提高。隨著製藥公司和研究人員專注於開發抗纖維化藥物、免疫抑制劑和標靶治療治療等創新治療方法，患者的治療結果和生活品質得到了顯著改善。然而，挑戰依然存在，包括治療成本上升、某些地區獲得治療方法的機會有限，以及需要繼續研究以闡明 IPF 的複雜性。此外，美國IPF 市場預計未來將維持持續的複合年成長率，突顯需要持續監測產業發展、新研究發現和監管更新。雖然這項見解凸顯了 IPF 市場的成長和創新潛力，但它也認知到要充分滿足患者需求並利用新興治療方法的優勢必須克服的障礙。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 技術分析
• 管道分析
• 專利分析

特發性肺纖維化市場：依藥物類型

• 市場概況
• 尼達尼布
• Pirfenidone
• 其他藥物類型

特發性肺纖維化市場：按作用機制

• 市場概況
• 抗纖維化劑
• 蛋白酪氨酸激酶抑制劑
• 其他作用機制

特發性肺纖維化市場：依最終用戶分類

• 市場概況
• 醫院和診所
• 藥局
• 其他最終用戶

特發性肺纖維化市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• United Therapeutics Corporation
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche Ltd
• FibroGen Inc.
• MediciNova Inc.
• Jubilant Pharma Limited（Jubilant Cadista Limited）
• Merck & Co. Inc.
• Horizon Therapeutics Inc.
• Avalyn Pharma Inc.
• AstraZeneca
• Novartis AG
• GlaxoSmithKline plc
• Genentech, Inc.
• Biogen Inc.
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Amgen Inc.

Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.50 billion in 2022 and is poised to grow from USD 4.02 billion in 2023 to USD 10.80 billion by 2031, growing at a CAGR of 6.98% during the forecast period (2024-2031).

The global Idiopathic Pulmonary Fibrosis (IPF) market is experiencing significant growth, driven by the rising incidence of this serious lung condition characterized by progressive lung tissue scarring and functional impairment. This expansion is largely attributed to advancements in diagnostic technologies that enhance early detection and enable better disease management, alongside increased awareness among healthcare professionals and patients for the need for timely intervention. As pharmaceutical companies and researchers focus on developing innovative treatment modalities-such as antifibrotic agents, immunosuppressants, and targeted therapies-patient outcomes and quality of life are notably improving. Nonetheless, challenges such as high treatment costs, restricted access to therapies in certain areas, and the necessity for ongoing research to unravel the complexities of IPF persist. Furthermore, the U.S. IPF market is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming years, highlighting the need for continuous monitoring of industry developments, new research findings, and regulatory updates. This insight emphasizes the potential for growth and innovation within the IPF market, while also acknowledging the obstacles that must be addressed to fully meet patient needs and harness the benefits of emerging therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Idiopathic Pulmonary Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Idiopathic Pulmonary Fibrosis Market Segmental Analysis

Global Idiopathic Pulmonary Fibrosis Market is segmented on the basis Global Idiopathic Pulmonary Fibrosis Market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Idiopathic Pulmonary Fibrosis Market

The Global Idiopathic Pulmonary Fibrosis (IPF) market is significantly propelled by relentless advancements in medical research and drug development aimed at unraveling the complex biology of IPF. This progress has led to the introduction of groundbreaking therapies, exemplified by antifibrotic agents such as Nintedanib and Pirfenidone, which have revolutionized treatment paradigms. These innovative options not only enhance survival rates but also markedly improve patients' quality of life, fueling patient demand and clinical adoption. As ongoing research continues to unveil new targets and treatment modalities, the market is poised for substantial growth, driven by a reinforced commitment to tackling this debilitating condition.

Restraints in the Global Idiopathic Pulmonary Fibrosis Market

One significant restraint in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the prohibitive cost of treatment options. Medications like Nintedanib and Pirfenidone, while effective, are priced at a premium, limiting accessibility for patients, particularly in lower-income regions. This financial burden can deter patients from pursuing necessary therapies, resulting in diminished adherence to treatment regimens and compromised disease management. Furthermore, the escalating treatment costs can strain healthcare systems, raising concerns about disparities in access to effective care for all IPF patients, thereby hindering market growth and sustainability in various global territories.

Market Trends of the Global Idiopathic Pulmonary Fibrosis Market

A prominent trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the growing emphasis on developing targeted therapies. Pharmaceutical companies and research institutions are directing resources toward innovative treatment modalities that specifically address the underlying mechanisms of IPF, offering a more personalized approach to patient care. This focus not only aims to enhance treatment efficacy but also seeks to mitigate side effects commonly associated with traditional therapies. As a result, targeted therapies are anticipated to revolutionize disease management, improving patient outcomes through tailored interventions. This trend signifies a paradigm shift towards precision medicine in the IPF landscape, reflecting the evolving needs of patients and healthcare systems worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Patent Analysis

Idiopathic Pulmonary Fibrosis Market, By Drug Type

• Market Overview
• Nintedanib
• Pirfenidone
• Other Drug Types

Idiopathic Pulmonary Fibrosis Market, By Mode of Action

• Market Overview
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other Modes of Action

Idiopathic Pulmonary Fibrosis Market, By End User

• Market Overview
• Hospitals and Clinics
• Pharmacies
• Other End Users

Idiopathic Pulmonary Fibrosis Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediciNova Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharma Limited (Jubilant Cadista Limited)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avalyn Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments